Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.verified

ATNM

Price:

$1.73

Market Cap:

$53.90M

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple...[Read more]

Industry

Biotechnology

IPO Date

2012-12-27

Stock Exchange

AMEX

Ticker

ATNM

The Enterprise Value as of November 2024 (TTM) for Actinium Pharmaceuticals, Inc. (ATNM) is -30290888.00

According to Actinium Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -30290888.00. This represents a change of -127.89% compared to the average of 108.61M of the last 4 quarters.

Actinium Pharmaceuticals, Inc. (ATNM) Historical Enterprise Value (quarterly & annually)

How has ATNM Enterprise Value performed in the past?

The mean historical Enterprise Value of Actinium Pharmaceuticals, Inc. over the last ten years is 64.30M. The current -30290888.00 Enterprise Value has changed -4811.00% with respect to the historical average. Over the past ten years (40 quarters), ATNM's Enterprise Value was at its highest in in the December 2014 quarter at 189.45M. The Enterprise Value was at its lowest in in the June 2022 quarter at 468.37K.

Quarterly (TTM)
Annual

Average

64.30M

Median

38.96M

Minimum

21.89M

Maximum

154.75M

Actinium Pharmaceuticals, Inc. (ATNM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Actinium Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 227.09%

Maximum Annual Enterprise Value = 154.75M

Minimum Annual Increase = -77.64%

Minimum Annual Enterprise Value = 21.89M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202360.58M-59.82%
2022150.78M227.09%
202146.10M44.84%
202031.83M29.00%
201924.67M-10.70%
201827.63M2.73%
201726.89M22.88%
201621.89M-77.64%
201597.87M-36.75%
2014154.75M20.30%

Actinium Pharmaceuticals, Inc. (ATNM) Average Enterprise Value

How has ATNM Enterprise Value performed in the past?

The current Enterprise Value of Actinium Pharmaceuticals, Inc. (ATNM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

85.82M

5-year avg

62.79M

10-year avg

64.30M

Actinium Pharmaceuticals, Inc. (ATNM) Enterprise Value vs. Peers

How is ATNM’s Enterprise Value compared to its peers?

Actinium Pharmaceuticals, Inc.’s Enterprise Value is less than MiNK Therapeutics, Inc. (23.96M), less than Affimed N.V. (50.05M), less than ImmunoGen, Inc. (8.19B), less than Adaptimmune Therapeutics plc (47.80M), less than Sangamo Therapeutics, Inc. (390.68M), less than Rigel Pharmaceuticals, Inc. (273.69M), less than Fortress Biotech, Inc. (59.35M), less than Reviva Pharmaceuticals Holdings, Inc. (30.20M), less than CTI BioPharma Corp. (1.22B), less than Ocuphire Pharma, Inc. (-9671816.00), less than Annovis Bio, Inc. (113.36M), less than Cassava Sciences, Inc. (1.04B), less than Axsome Therapeutics, Inc. (4.12B), less than Seres Therapeutics, Inc. (282.37M), less than Reviva Pharmaceuticals Holdings, Inc. (30.20M), less than Eyenovia, Inc. (57.40M), less than Cognition Therapeutics, Inc. (-9122761.00), less than TransCode Therapeutics, Inc. (5.63M), less than Kodiak Sciences Inc. (162.26M), less than Exelixis, Inc. (9.81B), less than TG Therapeutics, Inc. (3.89B), less than Viking Therapeutics, Inc. (7.57B), less than Madrigal Pharmaceuticals, Inc. (7.02B), less than BioXcel Therapeutics, Inc. (73.13M),

Build a custom stock screener for Actinium Pharmaceuticals, Inc. (ATNM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Actinium Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Actinium Pharmaceuticals, Inc. (ATNM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Actinium Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Actinium Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Actinium Pharmaceuticals, Inc. (ATNM)?

What is the 3-year average Enterprise Value for Actinium Pharmaceuticals, Inc. (ATNM)?

What is the 5-year average Enterprise Value for Actinium Pharmaceuticals, Inc. (ATNM)?

How does the current Enterprise Value for Actinium Pharmaceuticals, Inc. (ATNM) compare to its historical average?